ES2327168T3 - Formulacion de suspension de fexofenadina. - Google Patents
Formulacion de suspension de fexofenadina. Download PDFInfo
- Publication number
- ES2327168T3 ES2327168T3 ES06839331T ES06839331T ES2327168T3 ES 2327168 T3 ES2327168 T3 ES 2327168T3 ES 06839331 T ES06839331 T ES 06839331T ES 06839331 T ES06839331 T ES 06839331T ES 2327168 T3 ES2327168 T3 ES 2327168T3
- Authority
- ES
- Spain
- Prior art keywords
- approximately
- suspension according
- aqueous suspension
- volume
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229960003592 fexofenadine Drugs 0.000 title claims abstract description 75
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 title claims description 49
- 239000000725 suspension Substances 0.000 title description 30
- 239000000203 mixture Substances 0.000 title description 22
- 238000009472 formulation Methods 0.000 title description 9
- 239000007900 aqueous suspension Substances 0.000 claims abstract description 89
- 229930006000 Sucrose Natural products 0.000 claims abstract description 62
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims abstract description 62
- 239000005720 sucrose Substances 0.000 claims abstract description 60
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 claims abstract description 50
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims abstract description 50
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims abstract description 46
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims abstract description 45
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims abstract description 43
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims abstract description 43
- 239000000811 xylitol Substances 0.000 claims abstract description 43
- 235000010447 xylitol Nutrition 0.000 claims abstract description 43
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims abstract description 43
- 229960002675 xylitol Drugs 0.000 claims abstract description 43
- 239000000600 sorbitol Substances 0.000 claims abstract description 42
- 239000000243 solution Substances 0.000 claims abstract description 35
- -1 ion fexofenadine dihydrate Chemical class 0.000 claims abstract description 34
- 150000002500 ions Chemical class 0.000 claims abstract description 28
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims abstract description 25
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims abstract description 25
- 229960003415 propylparaben Drugs 0.000 claims abstract description 25
- 229940067596 butylparaben Drugs 0.000 claims abstract description 24
- 239000007853 buffer solution Substances 0.000 claims abstract description 23
- 150000004683 dihydrates Chemical class 0.000 claims abstract description 22
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims abstract description 20
- 239000002245 particle Substances 0.000 claims abstract description 20
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 18
- 235000003599 food sweetener Nutrition 0.000 claims abstract description 14
- 239000003765 sweetening agent Substances 0.000 claims abstract description 14
- 239000003755 preservative agent Substances 0.000 claims abstract description 10
- 230000002335 preservative effect Effects 0.000 claims abstract description 10
- 239000000080 wetting agent Substances 0.000 claims abstract description 9
- 239000000416 hydrocolloid Substances 0.000 claims abstract description 8
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims abstract description 6
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims abstract description 6
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims abstract description 6
- OGBHACNFHJJTQT-UHFFFAOYSA-M sodium;4-butoxycarbonylphenolate Chemical compound [Na+].CCCCOC(=O)C1=CC=C([O-])C=C1 OGBHACNFHJJTQT-UHFFFAOYSA-M 0.000 claims abstract description 6
- IXMINYBUNCWGER-UHFFFAOYSA-M sodium;4-propoxycarbonylphenolate Chemical compound [Na+].CCCOC(=O)C1=CC=C([O-])C=C1 IXMINYBUNCWGER-UHFFFAOYSA-M 0.000 claims abstract description 6
- TUMYXYVXTFDMTJ-UHFFFAOYSA-M potassium;4-propoxycarbonylphenolate Chemical compound [K+].CCCOC(=O)C1=CC=C([O-])C=C1 TUMYXYVXTFDMTJ-UHFFFAOYSA-M 0.000 claims abstract description 4
- 239000011734 sodium Substances 0.000 claims description 83
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 82
- 229910052708 sodium Inorganic materials 0.000 claims description 82
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 66
- 239000007971 pharmaceutical suspension Substances 0.000 claims description 63
- 229960004793 sucrose Drugs 0.000 claims description 58
- 229910019142 PO4 Inorganic materials 0.000 claims description 48
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 48
- 239000010452 phosphate Substances 0.000 claims description 48
- TWHXWYVOWJCXSI-UHFFFAOYSA-N phosphoric acid;hydrate Chemical compound O.OP(O)(O)=O TWHXWYVOWJCXSI-UHFFFAOYSA-N 0.000 claims description 34
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims description 28
- 229940045641 monobasic sodium phosphate Drugs 0.000 claims description 27
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims description 27
- 235000019799 monosodium phosphate Nutrition 0.000 claims description 27
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical group C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 25
- XVNVFKZODWAQKN-UHFFFAOYSA-N phosphoric acid;heptahydrate Chemical compound O.O.O.O.O.O.O.OP(O)(O)=O XVNVFKZODWAQKN-UHFFFAOYSA-N 0.000 claims description 23
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 21
- 229920001992 poloxamer 407 Polymers 0.000 claims description 21
- 229940044476 poloxamer 407 Drugs 0.000 claims description 21
- OVBJJZOQPCKUOR-UHFFFAOYSA-L EDTA disodium salt dihydrate Chemical compound O.O.[Na+].[Na+].[O-]C(=O)C[NH+](CC([O-])=O)CC[NH+](CC([O-])=O)CC([O-])=O OVBJJZOQPCKUOR-UHFFFAOYSA-L 0.000 claims description 20
- 229920001285 xanthan gum Polymers 0.000 claims description 19
- 239000000230 xanthan gum Substances 0.000 claims description 17
- 235000010493 xanthan gum Nutrition 0.000 claims description 17
- 229940082509 xanthan gum Drugs 0.000 claims description 17
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 15
- 239000006071 cream Substances 0.000 claims description 15
- 239000011591 potassium Substances 0.000 claims description 15
- 229910052700 potassium Inorganic materials 0.000 claims description 15
- 239000000872 buffer Substances 0.000 claims description 12
- 240000007651 Rubus glaucus Species 0.000 claims description 11
- 235000011034 Rubus glaucus Nutrition 0.000 claims description 11
- 235000009122 Rubus idaeus Nutrition 0.000 claims description 11
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims description 9
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 9
- 239000000796 flavoring agent Substances 0.000 claims description 8
- 235000013355 food flavoring agent Nutrition 0.000 claims description 8
- 230000003139 buffering effect Effects 0.000 claims description 7
- 235000011118 potassium hydroxide Nutrition 0.000 claims description 7
- DGLRDKLJZLEJCY-UHFFFAOYSA-L disodium hydrogenphosphate dodecahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].OP([O-])([O-])=O DGLRDKLJZLEJCY-UHFFFAOYSA-L 0.000 claims description 6
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 claims description 5
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 claims description 5
- 239000004302 potassium sorbate Substances 0.000 claims description 5
- 235000010241 potassium sorbate Nutrition 0.000 claims description 5
- 229940069338 potassium sorbate Drugs 0.000 claims description 5
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 5
- 239000004299 sodium benzoate Substances 0.000 claims description 5
- 235000010234 sodium benzoate Nutrition 0.000 claims description 5
- 239000004334 sorbic acid Substances 0.000 claims description 5
- 235000010199 sorbic acid Nutrition 0.000 claims description 5
- 229940075582 sorbic acid Drugs 0.000 claims description 5
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 claims description 4
- 239000005711 Benzoic acid Substances 0.000 claims description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 4
- 239000004376 Sucralose Substances 0.000 claims description 4
- 235000010233 benzoic acid Nutrition 0.000 claims description 4
- 229940067595 butylparaben sodium Drugs 0.000 claims description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 4
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 4
- 229940113115 polyethylene glycol 200 Drugs 0.000 claims description 4
- 229940068886 polyethylene glycol 300 Drugs 0.000 claims description 4
- 229940068918 polyethylene glycol 400 Drugs 0.000 claims description 4
- 235000019204 saccharin Nutrition 0.000 claims description 4
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 claims description 4
- 229940081974 saccharin Drugs 0.000 claims description 4
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 claims description 4
- 235000019408 sucralose Nutrition 0.000 claims description 4
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 4
- JACXUEYJJKTYSW-UHFFFAOYSA-N O.O.O.O.O.O.O.[Na] Chemical compound O.O.O.O.O.O.O.[Na] JACXUEYJJKTYSW-UHFFFAOYSA-N 0.000 claims description 3
- 235000019445 benzyl alcohol Nutrition 0.000 claims description 3
- 229920001993 poloxamer 188 Polymers 0.000 claims description 3
- 229940044519 poloxamer 188 Drugs 0.000 claims description 3
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 claims description 2
- 239000004909 Moisturizer Substances 0.000 claims description 2
- 235000013681 dietary sucrose Nutrition 0.000 claims description 2
- 230000001333 moisturizer Effects 0.000 claims description 2
- ZWJJGCJSVPNPIK-UHFFFAOYSA-N potassium;propyl 4-hydroxybenzoate Chemical compound [K].CCCOC(=O)C1=CC=C(O)C=C1 ZWJJGCJSVPNPIK-UHFFFAOYSA-N 0.000 claims description 2
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 claims 3
- RJRPCMREZGLMKP-UHFFFAOYSA-N [Ti].O=C=O Chemical group [Ti].O=C=O RJRPCMREZGLMKP-UHFFFAOYSA-N 0.000 claims 3
- 229910052719 titanium Inorganic materials 0.000 claims 3
- 239000010936 titanium Substances 0.000 claims 3
- 229960005359 propylparaben sodium Drugs 0.000 claims 2
- 235000010358 acesulfame potassium Nutrition 0.000 claims 1
- 229960004998 acesulfame potassium Drugs 0.000 claims 1
- 239000000619 acesulfame-K Substances 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 229940124274 edetate disodium Drugs 0.000 claims 1
- 229960002920 sorbitol Drugs 0.000 description 25
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 16
- RRJFVPUCXDGFJB-UHFFFAOYSA-N Fexofenadine hydrochloride Chemical compound Cl.C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RRJFVPUCXDGFJB-UHFFFAOYSA-N 0.000 description 11
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 11
- 229960000354 fexofenadine hydrochloride Drugs 0.000 description 11
- 239000000523 sample Substances 0.000 description 11
- 239000006185 dispersion Substances 0.000 description 9
- 229960003975 potassium Drugs 0.000 description 9
- 239000004408 titanium dioxide Substances 0.000 description 8
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 6
- 238000000634 powder X-ray diffraction Methods 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 238000000371 solid-state nuclear magnetic resonance spectroscopy Methods 0.000 description 5
- YNIRKEZIDLCCMC-UHFFFAOYSA-K trisodium;phosphate;hydrate Chemical compound [OH-].[Na+].[Na+].[Na+].OP([O-])([O-])=O YNIRKEZIDLCCMC-UHFFFAOYSA-K 0.000 description 5
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 4
- 229940008201 allegra Drugs 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 235000011121 sodium hydroxide Nutrition 0.000 description 4
- 239000013543 active substance Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000006184 cosolvent Substances 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 235000020937 fasting conditions Nutrition 0.000 description 3
- 238000007429 general method Methods 0.000 description 3
- 239000004570 mortar (masonry) Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 101100283604 Caenorhabditis elegans pigk-1 gene Proteins 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 230000005679 Peltier effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000008366 buffered solution Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 229940061607 dibasic sodium phosphate Drugs 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 238000002329 infrared spectrum Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 125000006353 oxyethylene group Chemical group 0.000 description 2
- CKRORYDHXIRZCH-UHFFFAOYSA-N phosphoric acid;dihydrate Chemical compound O.O.OP(O)(O)=O CKRORYDHXIRZCH-UHFFFAOYSA-N 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000001374 small-angle light scattering Methods 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 230000009747 swallowing Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- RMNIZOOYFMNEJJ-UHFFFAOYSA-K tripotassium;phosphate;hydrate Chemical compound O.[K+].[K+].[K+].[O-]P([O-])([O-])=O RMNIZOOYFMNEJJ-UHFFFAOYSA-K 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 238000001157 Fourier transform infrared spectrum Methods 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 229910007277 Si3 N4 Inorganic materials 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 229920003997 Torlon® Polymers 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940069078 citric acid / sodium citrate Drugs 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229940111685 dibasic potassium phosphate Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Polymers 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229940111688 monobasic potassium phosphate Drugs 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 238000001208 nuclear magnetic resonance pulse sequence Methods 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000013643 reference control Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000011863 silicon-based powder Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US75030305P | 2005-12-14 | 2005-12-14 | |
| US750303P | 2005-12-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2327168T3 true ES2327168T3 (es) | 2009-10-26 |
Family
ID=38120312
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES06839331T Active ES2327168T3 (es) | 2005-12-14 | 2006-12-12 | Formulacion de suspension de fexofenadina. |
Country Status (38)
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101546774B1 (ko) | 2008-07-29 | 2015-08-24 | 엘지전자 주식회사 | 휴대 단말기 및 그 동작제어 방법 |
| WO2013058996A1 (en) | 2011-10-19 | 2013-04-25 | R.P. Scherer Technologies, Llc | Two phase pharmaceutical delivery system |
| JP6410814B2 (ja) | 2013-07-01 | 2018-10-24 | アベンティスユービー・エルエルシー | フェキソフェナジンを含む経口投与用液体医薬組成物 |
| CN105358138A (zh) * | 2013-07-03 | 2016-02-24 | R.P.谢勒技术有限公司 | 包含非索非那定的胶囊制剂 |
| CN103610645B (zh) * | 2013-11-25 | 2016-05-11 | 浙江万晟药业有限公司 | 一种非索非那定盐酸盐的药物组合物及制备方法 |
| CN106806346B (zh) * | 2015-12-01 | 2020-09-11 | 国药集团广东环球制药有限公司 | 一种非索非那定盐酸盐干混悬剂制剂及其制备方法 |
| CN109906079B (zh) * | 2016-06-16 | 2022-09-30 | 库蒂斯制药公司 | 用于质子泵抑制剂混悬剂的组合物和方法 |
| JP7169671B2 (ja) | 2017-06-02 | 2022-11-11 | テイカ製薬株式会社 | 難水溶性成分可溶化ミセル及びそれを含有する液剤 |
| US11633478B2 (en) | 2019-07-16 | 2023-04-25 | Azurity Pharmaceuticals, Inc. | Compositions and kits for Omeprazole suspension |
| US10751333B1 (en) | 2019-07-16 | 2020-08-25 | Cutispharma, Inc. | Compositions and kits for omeprazole suspension |
| WO2022038474A1 (en) * | 2020-08-18 | 2022-02-24 | Innate S.R.L. | Injectable composition and use of said composition |
| WO2022175829A1 (en) | 2021-02-17 | 2022-08-25 | Cellix Bio Private Limited | Topical formulations and compositions |
| US20250082623A1 (en) * | 2021-12-29 | 2025-03-13 | Opella Healthcare Group Sas | Compositions containing fexofenadine |
| CN115715759B (zh) * | 2022-11-03 | 2024-01-12 | 京海盛达(北京)科技有限公司 | 一种抗组胺混悬剂及其制备方法 |
| CR20240566A (es) * | 2023-01-20 | 2025-02-25 | Opella Healthcare Group Sas | Formulaciones de fexofenadina sin parabenos |
| WO2026074306A1 (en) | 2024-10-03 | 2026-04-09 | Opella Healthcare Group Sas | Chewable fexofenadine tablets |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4254129A (en) | 1979-04-10 | 1981-03-03 | Richardson-Merrell Inc. | Piperidine derivatives |
| US4829064A (en) | 1987-06-08 | 1989-05-09 | Analgesic Associates | Cough/cold mixtures comprising non-sedating antihistamine drugs |
| CA2449419C (en) | 1994-05-18 | 2011-09-06 | Aventis Pharmaceuticals Inc. | Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof |
| US6132758A (en) | 1998-06-01 | 2000-10-17 | Schering Corporation | Stabilized antihistamine syrup |
| US6319513B1 (en) * | 1998-08-24 | 2001-11-20 | The Procter & Gamble Company | Oral liquid mucoadhesive compounds |
| GB9822170D0 (en) | 1998-10-13 | 1998-12-02 | Danbioyst Uk Ltd | Novel formulations of fexofenadine |
| US20060083691A1 (en) * | 2000-05-10 | 2006-04-20 | Wermeling Daniel P | Intranasal opioid compositions, delivery devices and methods of using same |
| DE60225694T2 (de) | 2001-07-31 | 2008-06-26 | Texcontor Etablissement | Neues polymorph von fexo-fenadin |
| US6723348B2 (en) * | 2001-11-16 | 2004-04-20 | Ethypharm | Orodispersible tablets containing fexofenadine |
| EP1587496B1 (en) * | 2003-01-30 | 2009-10-07 | Ethypharm | Taste-masking coated particles, process for the preparation thereof and orodispersible tablets containing said coated particles |
| US20050250737A1 (en) * | 2003-11-12 | 2005-11-10 | Allergan, Inc. | Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods |
| US20050266031A1 (en) | 2004-05-25 | 2005-12-01 | Jay Dickerson | Pharmaceutical suspension composition |
| DK2486942T3 (en) * | 2004-11-24 | 2019-01-28 | Meda Pharmaceuticals Inc | COMPOSITIONS CONTAINING AZELASTINE AND PROCEDURES FOR USING IT |
| AU2006278874A1 (en) | 2005-07-27 | 2007-02-15 | Sandoz Ag | A process for the preparation of substituted phenyl ether compounds and rosiglitazone |
| JP5133244B2 (ja) * | 2005-08-05 | 2013-01-30 | ルピン・リミテッド | フェキソフェナジンの経口用医薬懸濁組成物 |
-
2006
- 2006-12-06 DO DO2006000274A patent/DOP2006000274A/es unknown
- 2006-12-12 PL PL06839331T patent/PL1965768T3/pl unknown
- 2006-12-12 PT PT06839331T patent/PT1965768E/pt unknown
- 2006-12-12 SI SI200630374T patent/SI1965768T1/sl unknown
- 2006-12-12 CA CA2633086A patent/CA2633086C/en active Active
- 2006-12-12 PE PE2006001593A patent/PE20071003A1/es not_active Application Discontinuation
- 2006-12-12 WO PCT/US2006/047393 patent/WO2007070517A2/en not_active Ceased
- 2006-12-12 CN CN200680044516XA patent/CN101316580B/zh active Active
- 2006-12-12 NZ NZ568943A patent/NZ568943A/en not_active IP Right Cessation
- 2006-12-12 AT AT06839331T patent/ATE431137T1/de active
- 2006-12-12 MY MYPI20081743A patent/MY146988A/en unknown
- 2006-12-12 AR ARP060105470A patent/AR058323A1/es not_active Application Discontinuation
- 2006-12-12 BR BRPI0619895-3A patent/BRPI0619895B1/pt active IP Right Grant
- 2006-12-12 KR KR1020087014471A patent/KR101452792B1/ko not_active Expired - Fee Related
- 2006-12-12 ES ES06839331T patent/ES2327168T3/es active Active
- 2006-12-12 DE DE602006006870T patent/DE602006006870D1/de active Active
- 2006-12-12 EP EP06839331A patent/EP1965768B1/en active Active
- 2006-12-12 AU AU2006326551A patent/AU2006326551B2/en active Active
- 2006-12-12 JP JP2008545740A patent/JP5308824B2/ja not_active Expired - Fee Related
- 2006-12-12 RU RU2008128418/15A patent/RU2405538C2/ru not_active IP Right Cessation
- 2006-12-12 UA UAA200809121A patent/UA89584C2/uk unknown
- 2006-12-12 RS RSP-2009/0360A patent/RS51135B/sr unknown
- 2006-12-12 DK DK06839331T patent/DK1965768T3/da active
- 2006-12-12 HR HR20090411T patent/HRP20090411T1/hr unknown
- 2006-12-14 TW TW095146788A patent/TWI377061B/zh not_active IP Right Cessation
- 2006-12-14 JO JO2006458A patent/JO2549B1/en active
- 2006-12-15 UY UY30021A patent/UY30021A1/es not_active Application Discontinuation
-
2008
- 2008-04-24 TN TNP2008000186A patent/TNSN08186A1/en unknown
- 2008-05-06 ZA ZA200803985A patent/ZA200803985B/xx unknown
- 2008-05-20 CR CR9993A patent/CR9993A/es not_active Application Discontinuation
- 2008-06-11 IL IL192067A patent/IL192067A/en not_active IP Right Cessation
- 2008-06-12 EC EC2008008532A patent/ECSP088532A/es unknown
- 2008-06-13 HN HN2008000875A patent/HN2008000875A/es unknown
- 2008-06-13 US US12/138,468 patent/US8933097B2/en active Active
- 2008-06-15 EG EG2008060996A patent/EG25866A/xx active
- 2008-06-26 NO NO20082904A patent/NO339877B1/no not_active IP Right Cessation
- 2008-07-11 MA MA31103A patent/MA30152B1/fr unknown
-
2009
- 2009-08-12 CY CY20091100862T patent/CY1109320T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8933097B2 (en) | Fexofenadine suspension formulation | |
| JP3441676B2 (ja) | ジプラシドン組成物 | |
| Park et al. | Development of sorafenib loaded nanoparticles to improve oral bioavailability using a quality by design approach | |
| US20070015841A1 (en) | Pharmaceutical propylene glycol solvate compositions | |
| EA027869B1 (ru) | Стабилизированная композиция такролимуса | |
| ES2799512T3 (es) | Forma amorfa de un compuesto de pirimidinil-ciclopentano inhibidor de la AKT, composiciones y métodos de la misma | |
| KR20220101604A (ko) | 제약학적 공융 염 제제 | |
| ES2598168T3 (es) | Sistema cristalino de múltiples componentes que comprende deferasirox e isonicotinamida y procedimiento para la preparación del mismo | |
| KR102956339B1 (ko) | 피리다진온 trpc5 억제제의 분무 건조된 제형 | |
| ES2968899T3 (es) | Formulación de la solución oral | |
| TW201632188A (zh) | 配方 | |
| US8492423B2 (en) | Pharmaceutical propylene glycol solvate compositions | |
| HK1123197B (en) | Fexofenadine suspension formulation | |
| WO2013062497A1 (en) | Liquid pharmaceutical formulations | |
| JP7849382B2 (ja) | シロップ剤 | |
| CN114642656B (zh) | 一种吸入用尼达尼布溶液及其制备方法 | |
| TR201514760A1 (tr) | Rupatadi̇n i̇çeren yeni̇ oral çözelti̇ formülasyonu | |
| WO2025125509A1 (en) | Chemotherapeutic agent and compositions | |
| US20060105992A1 (en) | Pharmaceutical formulations of cyclodextrins and selective estrogen receptor modulator compounds | |
| Banu et al. | INVITRODRUG RELEASE STUDIES AND EVALUATION FOR CO-CRYSTALS OF ATAZANAVIR | |
| Malete et al. | A Review on Proniosomes | |
| MXPA99005524A (en) | Ziprasid formulations |